Having trouble accessing articles? Reset your cache.

Arzerra ofatumumab: Phase II data

Top-line data from an open-label, international Phase II trial in 97 patients showed that IV ofatumumab plus IV bendamustine led to an ORR of 95% in patients with previously untreated

Read the full 305 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE